Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.

Endocr Relat Cancer · 2025 · PMC12433830 · PMID 40888443

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Our study showed a trend toward a greater suppression of Ki-67 at 14 days in the palbociclib arm but no difference in Ki-67 suppression at surgery between arms, which is consistent with FELINE study.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.